Search the literature, browse cardiology by subspecialty, and follow where the evidence and consensus are moving.
Where the evidence has converged — synthesized from landmark RCTs and meta-analyses across cardiology.
High recent attention via X.
Evidence is strengthening on anticoagulant.
High recent attention via editorial coverage.
3 studies (63,185 patients) provide low-certainty evidence for benefit of rivaroxaban for Cardiac Output in Venous Thromboembolism.
Leading questionDoes rivaroxaban vs apixaban improve Cardiac Output in Venous Thromboembolism?44 new results in the last 60 days.
239 new results in the last 60 days.
28 new results in the last 60 days.
185 new results in the last 60 days.
41 new results in the last 60 days.
48 new results in the last 60 days.
14 new results in the last 60 days.
11 new results in the last 60 days.
4 new results in the last 60 days.
Does dapagliflozin vs placebo affect OUT:cv-death-or-worsening-hf in Heart Failure with Reduced Ejection Fraction?
1 studies (4,744 patients, 1 RCTs) provide moderate-certainty evidence for benefit of dapagliflozin for Composite of worsening HF or cardiovascular death in Heart Failure with Reduced Ejection Fraction.
1 RCTs · 4,744 ptsDoes oral anticoagulation vs placebo improve All-Cause Mortality in Atrial Fibrillation?
22 studies (1,391,103 patients) provide low-certainty evidence for benefit of oral anticoagulation for All-Cause Mortality in Atrial Fibrillation.
1,391,103 ptsDoes immune checkpoint inhibitors vs placebo improve outcomes in cancer therapy-related cardiovascular toxicity?
22 studies (459,509 patients) provide low-certainty evidence for benefit of immune checkpoint inhibitors for Cardiac Index in cancer therapy-related cardiovascular toxicity.
459,509 ptsDoes exenatide vs placebo improve All-Cause Mortality in Diabetes Mellitus, Non-Insulin-Dependent?
5 studies (44,256 patients) provide low-certainty evidence for benefit of exenatide for All-Cause Mortality in Diabetes Mellitus, Non-Insulin-Dependent.
44,256 ptsDoes ticagrelor vs clopidogrel improve Myocardial Infarction Hospitalization in Acute Coronary Syndrome?
3 studies (41,464 patients) provide low-certainty evidence for benefit of ticagrelor for Myocardial Infarction Hospitalization in Acute Coronary Syndrome.
41,464 ptsDoes dabigatran vs warfarin improve outcomes in HEART-VALVE, MECHANICAL?
3 studies (0 patients) provide low-certainty evidence for benefit of dabigatran for Ventricular Arrhythmia in HEART-VALVE, MECHANICAL.
Does amiodarone vs placebo improve outcomes in Atrial Fibrillation?
10 studies (49,075 patients) provide low-certainty evidence against benefit of amiodarone for Myocardial Infarction Hospitalization in Atrial Fibrillation.
49,075 ptsDoes asparaginase vs placebo improve outcomes in L2 Acute Lymphoblastic Leukemia?
4 studies (221 patients) provide low-certainty evidence against benefit of asparaginase for Myocardial Infarction Hospitalization in L2 Acute Lymphoblastic Leukemia.
221 ptsDoes dipyridamole vs placebo improve Left Ventricular Ejection Fraction in Aortic Valve Stenosis?
2 studies (30 patients) provide low-certainty evidence against benefit of dipyridamole for Left Ventricular Ejection Fraction in Aortic Valve Stenosis.
30 ptsCreate a free account to filter by intervention × outcome, follow individual questions, and get notified as new RCTs change the picture.